OR WAIT 15 SECS
Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to Beckman Coulter Genomics.
Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to form Beckman Coulter Genomics. The new company is expected to offer researchers a single genomic services resource with expanded global capabilities.
"Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry's leading genomic service providers to offer our customers the highest quality data and analysis," said Richard Creager, PhD, Beckman Coulter group vice president of immunoassay, molecular diagnostics and genomic services, in a statement.
Services currently available through the new company are reported to include sequencing, sample preparation, genotyping, gene expression, biological efficiency and safety testing, with support for all levels of regulatory compliance, including Clinical Laboratory Improvement Amendments (CLIA).
The new company has offices throughout North America and Europe.